Vandortuzumab, a novel immunoglobulin, represents an intriguing medicinal agent targeting CD40, a key molecule involved in immune response. Its mechanism of action entails modulating CD40 signaling, seemingly causing https://www.targetmol.com/compound/vandortuzumab